We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing to The Nasdaq Capital Market. This marks an exciting and significant milestone for our company as we continue to build on our success and advance our technologies to one day benefit patients everywhere.

Today, we reflect on our journey over the past few years and what we have accomplished to date: an industry-leading intratumoral immunotherapy pipeline, a state-of-the-art technology platform, key industry and academic collaborations, a diverse range of research programs, and an employee culture aligned with our values and purpose.

Thanks to the ambition and creativity of our OncoSec employees, we continue to champion our company’s purpose to deliver new cancer treatments through innovative science. Looking to the future, we hope to continue to validate our technology through our clinical and preclinical programs and build even more value for our shareholders.

OncoSec has never been stronger in terms of our technology, immuno-oncology pipeline, and key collaborations. With this in mind, our team is poised to ‘ring’ in a new – and long awaited – era of cancer care.

The statements or opinions expressed on this site are my own and do not necessarily represent those of my employer OncoSec Medical.

Punit Dhillon